LivaNova PLC was established in 2015 through the merger of Cyberonics and Sorin Group, creating a specialized medical device manufacturer with operations in over 100 countries. The company's Cardiopulmonary segment provides critical equipment for cardiac surgery, including heart-lung machines, oxygenators, and autotransfusion systems. Its Neuromodulation segment focuses on implantable pulse generators that deliver Vagus Nerve Stimulation (VNS) therapy to treat drug-resistant epilepsy and difficult-to-treat depression, alongside developing treatments for obstructive sleep apnea. LivaNova distributes its products to hospitals, surgeons, and specialized medical centers through a mix of direct sales representatives and independent distributors. By concentrating on complex, high-impact therapies, the company maintains a strong competitive position in both extracorporeal life support and neuromodulation technologies.
